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ABSTRACT
Background    The human leukocyte antigen (HLA) 
region has been found to be involved in the pathogenesis 
of inflammatory bowel disease (IBD), which is classified 
into ulcerative colitis (UC) and Crohn’s disease (CD), by 
genome-wide association studies. The aim of this study 
was to confirm whether HLA-alleles confer susceptibil-
ity to UC and to determine whether HLA-allel1es are 
associated with the clinical phenotypes in Japanese pa-
tients with UC. 
Methods    In this study, HLA typing was performed by 
PCR-sequence-specific oligonucleotides (PCR-SSO) to 
confirm the correlation between UC and HLA alleles (for 
HLA-A, B, DRB1) in 45 Japanese UC patients. In addi-
tion, whether the HLA alleles are related to patient and 
clinical background characteristics was examined. 
Results    Overall, 62.2%, and 66.7% of the 45 UC pa-
tients had HLA-B*52 and HLA-DRB1*15, respectively. 
These allele frequencies were significantly higher than 
in previously reported Japanese control persons (P < 
0.0001). The frequencies of extraintestinal manifesta-
tions [odds ratio (OR) = 0.12, P = 0.039] and a history 
of colectomy (OR = 0.18, P = 0.046) were lower in 
HLA-B*52-positive UC patients than in HLA-B*52 neg-
ative UC patients. The white blood cell (WBC) count 
was significantly higher in HLA-DRB1*15-positive 
patients (9430 ± 4592/μL) than in HLA-DRB1*15-neg-
ative patients (6729 ± 2160/μL). Thus, HLA-B*52 and 
DRB1*15 appear to be associated with disease features 
and severity in Japanese UC patients. 
Conclusion    These results indicate that HLA-B*52 
and DRB1*15 are not only associated with overall UC 
susceptibility, but also with the clinical phenotypes in 
Japanese patients.
Key words    HLA; inflammatory bowel disease; Japa-
nese; ulcerative colitis 
Inflammatory bowel disease (IBD), an autoimmune 
disease (AD) of the gastrointestinal tract, consists of two 
clinical forms, Crohn’s disease (CD) and ulcerative coli-
tis (UC). IBD has a complex etiology involving multiple 
genetic and environmental factors.1 The past three de-
cades have seen an exponential increase in the incidence 
and prevalence of both CD and UC in Japan.2 Several 
genome-wide studies have confirmed that UC and CD 
are connected to chromosome 6p21.1-23, which has been 
named IBD3 and overlaps with the human leukocyte an-
tigen (HLA) region.3–6
 The human HLA region is highly polymorphic,7 
some of which may predispose to particular ADs.8 
Class-I molecules (HLA-A and -B) are recognized by 
receptors on CD8-positive suppressor T cells, while 
class-II molecules (HLA-DRB1) are recognized by 
receptors on CD4-positive helper T cells when attack-
ing and eliminating foreign substances. Through this 
mechanism, HLA molecules are involved in not only the 
recognition of self or non-self, but also self-defense and 
pathogenesis of diseases. Previous studies have reported 
that HLA alleles were associated with UC susceptibility 
and phenotype. However, only a few reports evaluated 
the contribution of HLA-alleles to the clinical pheno-
type of Japanese UC patients.9, 10 In this study, whether 
HLA-alleles confer susceptibility to UC was confirmed, 
and whether HLA-alleles are associated with the clinical 
phenotypes in Japanese patients with UC was investigat-
ed.
SUBJECTS AND METHODS
Patients
A total of 45 Japanese patients [20 men, 25 women, 
mean age (range) 45.8 ± 14.5 (range 22–74) years] with 
UC from the Tottori University Hospital were included 
between January 2015 and December 2016. The diag-
nosis of UC in all subjects was made by gastroenterol-
ogists based on clinical, radiological, endoscopic, and 
histological features according to the 2010 criteria of the 
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Japanese Research Committee of Inflammatory Bowel 
Disease.11 
Clinical characteristics
The following characteristics of the 45 patients were 
examined: sex, age at disease onset, smoking, disease 
extent, gastrointestinal (GI) complications and extrain-
testinal manifestations. The following laboratory data 
were also examined: WBC count, hemoglobin, platelets, 
erythrocyte sedimentation rate (ESR) and C-reactive 
protein (CRP). The treatments administered to the pa-
tients were also analyzed. The data at diagnosis or the 
first visit were used in this study.
HLA typing
HLA allele typing was performed for the 45 UC patients 
(44 patients for HLA-DRB1) using PCR-sequence-spe-
cific oligonucleotide (BIOMEDICAL LABORATO-
RIES, Tokyo, Japan). Frequencies of HLA alleles 
(HLA-B, DRB1) in the patients were compared with 
those in the previously reported Japanese controls.12 
Clinical characteristics were compared between the sub-
groups with or without the disease-associated HLA al-
leles. Approval was obtained from the Ethics Committee 
of the institute in accordance with the provisions of the 
World Medical Association’s Declaration of Helsinki. 
All patients gave their informed consent to be involved 
in the protocol, which was approved by the Institutional 
Review Board of Tottori University (1701A175).
Statistical analysis
The chi-square test was used for categorical variables. 
Mann-Whitney’s U-test was used to compare patients’ 
ages at onset and laboratory data. P-values < 0.05 were 
considered significant. All statistical analyses were per-
formed using Stat Flex (ver. 6.0; Artech, Osaka, Japan).
RESULTS
Patient and clinical characteristics
The characteristics of the patients with UC are shown 
in Table 1. The average age of the 45 UC patients was 
45.8 ± 14.5 years; 25 patients (55.6%) were female. The 
average age of disease onset was 32.1 ± 13.7 years, and 
34 patients (75.6%) were younger than 40 years at onset. 
Five patients had a family history of UC. Eight patients 
(17.8%) were ex- and current smokers. The most com-
mon disease extent was total colitis, followed by left-sid-
ed colitis and proctitis. Seven patients had a history of 
rectocolectomy for UC. No patients had a history of 
appendectomy.
 Initial laboratory data showed the following: WBC 
count 8527 ± 4117/μL, hemoglobin 12.8 ± 2.0 g/dL, 
Table 1. Clinical characteristics of 45 patients with UC
Male:Female (n) 20:25
Age at entry (y) 45.8 ± 14.5
Age at onset (y) 32.1 ± 13.7
≤ 40 y 34 (75.6%)
> 40 y 11 (24.4%)
Family history of UC 5 (11.1%)
Smoking habit
Current smoker 3 (6.7%)
Ex-smoker 5 (11.1%)
Disease extent
Proctitis 9 (20.0%)
Left-sided colitis 12 (26.7%)
Total colitis 24 (53.3%)
GI complications 4 (8.9%)
Extraintestinal manifestations 5 (11.1%)
Articular 1 (2.2%)
Dermatological 2 (4.4%)
Other 2 (4.4%)
Values are means ± SD or numbers (percentage) unless indicated 
otherwise. GI, gastrointestinal; UC, ulcerative colitis; y, years.
Table 2. Laboratory data and treatments of 45 UC pa-
tients 
Laboratory data
WBC (/μL) 8527 ± 4117
Hemoglobin (g/dL) 12.8 ± 2.0
Platelets (× 104/mm3) 31.0 ± 12.4
ESR (mm/hour) 31.0 ± 30.1
CRP (mg/dL) 1.2 ± 2.5
Treatment
Corticosteroids 2 (4.4%)
Ever corticosteroids 32 (71.1%) 
5-aminosalicylic acid 36 (80.0%)
Immunosuppressants 15 (33.3%)
Biologics 9 (20.0%)
Surgical treatment (rectocolectomy) 7 (15.6%)
Values are means ± SD or numbers (percentage) unless indicated 
otherwise. CRP, C-reactive protein; ESR, erythrocyte sedimenta-
tion rate; UC, ulcerative colitis; WBC, white blood cell.
platelets 31.0 ± 12.4 × 104/mm3, ESR 31.0 ± 30.1 mm/
hour and CRP 1.2 ± 2.5 mg/dL (Table 2). A total of 32 
patients (71.1%) had been treated with glucocorticoids, 
whereas immunosuppressive agents were prescribed in 
15 patients (33.3%) and biologics in 9 patients (20.0%). 
Surgical treatment (rectocolectomy) was performed in 7 
patients (15.6%), as described above. 
HLA phenotype and allele frequencies
Table 3 summarizes the results of the HLA analysis. 
Only the alleles showing significant associations with 
UC are shown. As for the class I alleles, the frequency 
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Table 3. Association of HLA with Ulcerative colitis
Patients Controls
n PF AF n AF P value Odds ratio
HLA-B*52 45 62.2% 31.1% 1023 10.7% < 0.0001 3.79
HLA-DRB1*15 44 68.2% 36.4% 898 17.4% < 0.0001 2.72
AF, allele frequency; HLA, human leukocyte antigen; PF, phenotype frequency.
Table 4. Associations of the HLA-B*52 allele with clinical characteristics in 45 UC patients
HLA-B*52 (+) HLA-B*52 (–) P value Odds ratio 95% CI
(n = 28) (n = 17)
Male:Female (n) 13:15 7:10 0.73 0.81 0.24–2.73
Age at onset (y) 34.1 ± 13.8 28.8 ± 13.4 0.19 – –
> 40 y 9 (32.1%) 2 (11.8%) 0.12 3.55 0.71–17.79
Family history of UC 4 (14.3%) 1 (5.9%) 0.38 2.67 0.29–24.32
Smoking
Never smoker 24 (85.7%) 13 (76.5%) 0.43 1.85 0.40–8.51
Current smoker 1 (3.6%) 2 (11.8%) 0.29 0.28 0.026–2.91
Former smoker 3 (10.7%) 2 (11.8%) 0.91 0.90 0.13–6.02
Disease extent
Proctitis 6 (21.4%) 3 (17.6%) 0.76 1.27 0.27–5.92
Left-sided colitis 8 (28.6%) 4 (23.5%) 0.71 1.30 0.32–5.20
Total colitis 14 (50.0%) 10 (58.8%) 0.57 0.70 0.21–2.36
GI complications 1 (3.6%) 3 (17.6%) 0.11 0.17 0.020–1.47
Extraintestinal manifestations 1 (3.6%) 4 (25.5%) 0.039* 0.12 0.016–0.90
WBC (/μL) 8421 ± 3655 8700 ± 4900 0.93 – –
Hemoglobin (g/dL) 13.2 ± 2.0 12.1 ± 2.0 0.068 – –
Platelets (× 104/mm3) 30.2 ± 12.2 32.3 ± 13.0 0.36 – –
ESR (mm/hour) 30.1 ± 30.5 32.5 ± 30.3 0.96 – –
CRP (mg/dL) 1.39 ± 2.84 1.00 ± 2.03 0.62 – –
5-aminosalicylic acid 24 (85.7%) 12 (70.6%) 0.22 2.50 0.58–10.77
Corticosteroids 1 (3.6%) 1 (5.9%) 0.72 0.59 0.036–9.86
Ever corticosteroids 20 (71.4%) 12 (70.6%) 0.95 1.04 0.28–3.93
Immunosuppressants 10 (35.7%) 5 (29.4%) 0.66 1.33 0.36–4.88
Biologics 6 (21.4%) 3 (17.6%) 0.76 1.27 0.27–5.92
Surgical treatment 2 (7.1%) 5 (29.4%) 0.046* 0.18 0.035–0.97
Values are means ± SD or numbers (percentage) unless indicated otherwise. *P < 0.05. CI, confidence interval; CRP, C-reactive protein; 
ESR, erythrocyte sedimentation rate; GI, gastrointestinal; HLA, human leukocyte antigen; UC, ulcerative colitis; WBC, white blood cell; y, 
years.
of HLA-B*52 was significantly higher in patients than in 
controls [31.1% versus 10.7%, odds ratio (OR) 3.79, P < 
0.0001]. As for the class II alleles, there was a significant 
positive association between UC and HLA-DRB1*15 
(36.4% versus 17.4%, OR 2.72, P < 0.0001). 
HLA typing and comparison with patient and clini-
cal characteristics
The results of HLA typing in 45 UC patients were com-
pared with patient and clinical characteristics. Patient 
and clinical characteristics were compared between the 
HLA-B* 52-positive and -negative patients, as shown in 
Table 4. The incidence of extraintestinal manifestations 
was lower in HLA-B*52-positive UC patients (3.6%) 
than in HLA-B*52-negative UC patients (25.5%) (P = 
0.039, OR0.12). The frequency of a history of colectomy 
was lower in HLA-B*52-positive patients (7.1%) than 
in HLA-B*52-negative patients (29.4%) (P = 0.046, OR 
0.18). The clinical characteristics were also compared 
between the HLA-DRB1*15-positive and -negative 
groups, as shown in Table 5. The WBC level was sig-
nificantly higher in the HLA-DRB1*15-positive patients 
(9430 ± 4592/μL) than in the HLA-DRB1*15-negative 
patients (6729 ± 2160/μL). The lymphocyte level was sig-
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Table 5. Associations of the HLA-DRB1*15 allele with clinical characteristics in 44 UC patients
HLA-DRB1*15 HLA-DRB1*15 P value Odds ratio 95% CI
(+)(n = 30) (–)(n = 14)
Male:Female (n) 13:17 7:7 0.68 1.31 0.37–4.66
Age at onset (y) 34.5 ± 14.5 27.1 ± 11.3 0.11 – –
≤ 16 y 4 (13.3%) 3 (21.4%) 0.49 0.56 0.11–2.91
17–40 y 16 (53.3%) 10 (71.4%) 0.26 0.46 0.12–1.76
> 40 y 10 (33.3%) 1 (7.1%) 0.061 6.50 0.91–46.29
Family history of UC 3 (10.0%) 1 (7.1%) 0.76 1.44 0.14–15.10
Smoking
Never smoker 24 (80.0%) 12 (85.7%) 0.65 0.67 0.12–3.78
Current smoker 2 (6.7%) 1 (7.1%) 0.95 0.93 0.077–11.18
Former smoker 4 (13.3%) 1 (7.1%) 0.55 2.00 0.21–19.06
Disease extent
Proctitis 4 (13.3%) 5 (35.7%) 0.087 0.28 0.064–1.20
Left-sided colitis 10 (33.3%) 2 (14.3%) 0.19 3.00 0.59–15.30
Total colitis 16 (53.3%) 7 (50.0%) 0.84 1.14 0.32–4.07
GI complications 1 (3.3%) 3 (21.4%) 0.052 0.13 0.016–1.02
Extraintestinal manifestations 2 (6.7%) 3 (21.4%) 0.15 0.26 0.042–1.63
WBC (/μL) 9430 ± 4592 6729 ± 2160 0.049* – –
Neutrophil (/μL) 6611 ± 4237 4468 ± 1849 0.15 – –
Lymphocyte (/μL) 1958 ± 745 1371 ± 428 0.006* – –
Monocyte (/μL) 579 ± 244 625 ± 350 0.84 – –
Eosinophil (/μL) 263 ± 248 238 ± 252 0.45 – –
Basophil (/μL) 55 ± 85 36 ± 37 0.95 – –
NLR 3.9 ± 3.5 3.7 ± 2.2 0.71 – –
Hemoglobin (g/dL) 12.7 ± 2.0 13.1 ± 2.2 0.75 – –
Platelets (× 104/mm3) 31.6 ± 13.2 29.3 ± 11.1 0.88 – –
ESR (mm/hour) 31.6 ± 29.6 30.7 ± 33.2 0.39 – –
CRP (mg/dL) 1.32 ± 2.75 1.18 ± 2.21 0.94 – –
5-aminosalicylic acid 25 (83.3%) 10 (71.4%) 0.36 2.00 0.45–8.87
Corticosteroids 1 (3.3%) 1 (7.1%) 0.57 0.45 0.028–7.25
Ever corticosteroids 24 (80.0%) 8 (57.1%) 0.11 3.00 0.77–11.66
Immunosuppressants 11 (36.7%) 4 (28.6%) 0.60 1.45 0.27–5.72
Biologics 7 (23.3%) 2 (14.3%) 0.49 1.83 0.33–10.03
Surgical treatment 3 (10.0%) 4 (28.6%) 0.12 0.28 0.056–1.38
Values are means ± SD or numbers (percentage) unless indicated otherwise. *P < 0.05. CI, confidence interval; CRP, C-reactive protein; 
ESR, erythrocyte sedimentation rate; GI, gastrointestinal; HLA, human leukocyte antigen; NLR, neutrophil–lymphocyte ratio; UC, ul-
cerative colitis; WBC, white blood cell.
nificantly higher in the HLA-DRB1*15-positive patients 
(1958 ± 745/μL) than in the HLA-DRB1*15-negative 
patients (1371 ± 428/μL), but no significant difference 
was observed with respect to neutrophil-lymphocyte 
ratio (NLR) between these two groups. No significant 
differences were found in the allele frequencies for other 
clinical background characteristics.
DISCUSSION
Recently, several linkage and association studies for IBD 
including UC were reported, and several susceptibility 
loci, including the HLA region, were identified.13–18 In 
the Japanese population, a previous study suggested an 
association between UC and HLA.19–23 In the present 
study, whether HLA-A/B/DRB1 alleles confer suscep-
tibility to UC or determine the clinical phenotype of 
UC was examined. It was found that HLA-B*52, and 
DRB1*15 contribute to susceptibility and the clinical 
phenotype in Japanese UC patients.
 Previous association studies of HLA showed several 
associated alleles and haplotypes of HLA in patients 
with UC, although HLA typing differs by race and 
region.24 Among the associated alleles, HLA-B*52 is 
well known to be strongly associated with UC in Japa-
nese patients.10, 19–21 According to Arimura and others’ 
2014 meta-analysis of Japanese IBD genetics,14 HLA-
DRB1*1502 was confirmed to have a positive associa-
tion with UC. The results of the present study showed 
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that the frequencies of HLA-B*52 and DRB1*15 alleles 
in UC patients were higher than in previously report-
ed Japanese controls.12 Therefore, these results were 
compatible with the previously reported associations of 
HLA-B*5201 and DRB1*1502 with UC.10, 21, 25, 26 
 Asakura and others reported significant associa-
tions between UC and HLA-B*52 and DRB1*15 haplo-
types in Japanese populations.19 Furthermore, it is well 
known that a conserved haplotype of HLA A*24-B*52-
DRB1*1502-DQB1*0601-DPB1*0901 is strongly associ-
ated with UC in the Japanese population.20 Interestingly, 
HLA-A*24-B*52-DRB1*15 haplotype is a characteristic 
of the Japanese population (8.7%).27 Thus, it appears that 
a genetic factor plays an important role in the pathogen-
esis of UC. Okada and others reported that a particular 
HLA haplotype, HLA-Cw*1202-B*5201-DRB1*1502, 
increases susceptibility to UC but reduces the risk for 
CD.13 Thus, use of the information about HLA alleles 
might contribute to improvements in the diagnostic 
approaches to UC and CD. In addition to prediction of 
UC susceptibility, HLA typing could assist in the dis-
crimination of UC from CD. Moreover, the pathological 
relevance of the HLA haplotype requires further inves-
tigation. Indeed, advancing microbiome technology has 
recently demonstrated the interaction of HLA genotypes 
with microbiota as a representative environmental factor. 
For example, T cell responsiveness to specific microbio-
ta depends on HLA genotypes.28
 In the present study, whether the HLA alleles were 
associated with the characteristics of UC was also 
investigated. In prior studies, it was reported that the 
HLA-B*52 allele is associated with younger age at on-
set of UC in Japan.10 In contrast, Matsumura and others 
reported that HLA-DRB1*09 was associated with older 
age of onset.9 However, similar results were not obtained 
in this study. Monsen and others raised the possibility 
that a major gene may be associated with a separate 
type of UC with more extensive involvement, younger 
age of onset, and more immunologic side effects, such 
as extraintestinal manifestations.29, 30 Surprisingly, in 
the present study, the HLA-B*52 allele frequency was 
lower in the group with extraintestinal manifestations 
and with a history of colectomy than in those with-
out. These results may be due to the improvement of 
UC treatment, as with biologics. The WBC count was 
higher in the present HLA-DRB1*15-allele-positive 
group than in the HLA-DRB1*15-allele-negative group. 
Matsumura and others reported that HLA-DRB1*08 is 
associated with disease extent in Japanese UC patients,9 
which might suggest an association of the HLA-DRB1 
allele with more active and severe disease. Similarly, 
Futami and others reported that HLA-DRB1*1502 was 
associated with disease severity in patients with UC.31 
Thus, HLA typing is likely to be useful in the predic-
tion of the disease course in patients with an established 
diagnosis of UC. Whereas, the lymphocyte count was 
higher in the HLA-DRB1*15-allele-positives than in 
the HLA-DRB1*15-allele-negatives, but no significant 
difference was observed with respect to NLR between 
these two groups. Recent studies demonstrated that NLR 
was higher in patients with active UC.32,33 NLR may be 
affected by the use of corticosteroids, hematological or 
neoplastic disorders, chronic liver disease, and clinical 
evidence of active infection. In this study, the data were 
obtained at diagnosis or the first visit. From this point of 
view, HLA-DRB1*15 may not affect the disease activity 
in UC.
 Contradictory results on the association between 
HLA alleles and UC phenotypes compared with pre-
vious studies may be due to the limited size, methods 
used, clinical courses of the UC patients selected, and 
heterogeneity of the populations studied. Moreover, 
since the present study involved only a small number 
of patients and was limited by its retrospective nature, 
more cases are required in future studies to confirm the 
involvement of the HLA alleles in susceptibility and 
clinical characteristics of UC patients. 
 In conclusion, the results of the present study 
showed that HLA-B*52 and HLA-DRB1*15 are not only 
associated with overall UC susceptibility, but also with 
the clinical phenotypes in Japanese patients. These ob-
servations suggest that both susceptibility and the clini-
cal characteristics of UC patients were controlled in part 
by the HLA-alleles. Further analysis of these phenotypes 
and subgroup analysis may elucidate how these alleles 
contribute to screening, susceptibility, and treatment in 
UC patients
The authors declare no conflict of interest.
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